Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Computational Pathology, AI & Precision Diagnostics

PART OF Biomarkers, CDx & Precision Medicine US

23 - 24 September 2026 | Gaylord Pacific Resort & Convention Center, San Diego, CA

Programme Summary

The Computational Pathology, AI & Precision Diagnostics programme takes the precision medicine decision chain through to deployment: foundation models for biomarker discovery, AI in pathology workflows, computational biomarker analysis, AI-enabled stratification, and the regulatory journey for AI/ML-based CDx.

At the heart of the programme is the Day 2 track keynote from AstraZeneca on scaling computational pathology for the next generation of cancer therapies, supported by three dedicated tracks across the two days.

The wider event sits around it: the cross-programme regulatory panel on AI-derived biomarkers and CDx, the integrated diagnostics panel and direct connection points to the biomarker and multi-omics work throughout.

Computational Pathology Top Image

Day 2 Track Keynote

MARK GUSTAVSON, AstraZeneca

Mark Gustavson leads computational pathology work inside AstraZeneca's oncology R&D, focused on scaling AI-driven pathology platforms across the company's late-stage cancer therapy programmes. His session covers how computational pathology moves from proof-of-concept to a routine part of biomarker-driven drug development, and what scaling means in practice for AI/ML model validation, deployment and regulatory positioning.

Mark Gustavson Headshot

2026 Highlights

The track keynote from Mark Gustavson of AstraZeneca anchors the programme, on scaling computational pathology for the next generation of cancer therapies.

Lauri Diehl (Gilead) covers foundation models for biomarker discovery whilst Wei-Ju Tseng (GSK) covers advancing precision medicine with AI-integrated histopathology imaging.

Plus sessions on computational biomarker analysis, AI/ML model validation pathways, and AI in pathology workflows. The Day 1 cross-programme regulatory panel covers what Merck, AstraZeneca's senior regulatory voices expect from AI-derived biomarkers and computational pathology CDx in 2026.

NextGen Biomed - What to Expect Networking 4
Our Community and Culture Circle Image
600

leading pharma, biotech, regulatory & academic delegates

700
pre-arranged 1-2-1 meetings, facilitating business growth
50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including fireside chats & refreshments

Computational Pathology, AI & Precision Diagnostics Agenda at a Glance

DAY ONE

Track 6: Computational Pathology, Image Analysis & AI 

DAY TWO

Track 5: AI-Powered Image Analysis, for Spatial Biology & Computational Pathology
Track 6: Utilizing Computational Pathology in Pharma Research & Commercialization

BIOMEU On Page Agenda

Key Event Highlights

An unmissable journey awaits you: from celebrated keynote speakers and insightful private roundtables, to an exclusive gala dinner. Discover the moments that will transform your NextGen Omics & Spatial experience. 

Featured Speakers for Computational Pathology, AI & Precision Diagnostics US 2026

Lauri Diehl
Executive Director Pathobiology,
Gilead Sciences
Suzanne Coberly
Senior Director, Research Pathology,
Bristol Myers Squibb
Show More Speakers
Hide Speakers
Cheng Cui
Senior Translational Regulatory Affairs Director,
AstraZeneca
Guneet Walia
Senior Director, Data Science & Digital Health,
Janssen Pharmaceutical Companies of Johnson & Johnson
Jennifer Giltnane
Anatomical Pathologist, Clinical Research,
Merck
Karen McCullough
Vice President, Oncology Regulatory Strategy,
AstraZeneca
Kristopher Standish
Senior Director, Data Science, AI/Computer Vision,
Johnson & Johnson
Mark Gustavson
Senior Director, Computational Pathology,
AstraZeneca
Reena Philip
Executive Director, Regulatory Liaison, Companion Diagnostics / In Vitro Diagnostics,
Merck
Sripad Ram
Director,
Pfizer Inc
Sriram Sridhar
Senior Director Translational Data Science,
Genmab
Stefan Hamann
Senior Principal Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Wei-Ju Tseng
Associate Director, Digital Histology,
GSK

Interested in Sponsoring Computational Pathology, AI & Precision Diagnostics?

Connect with 600+ senior pharma R&D leaders, computational pathologists, AI platform heads and digital pathology programme leads. 74% of delegates at the last edition were actively seeking new solutions.

Pre Med + LSX Combined Logo

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things Precision Medicine, direct to your inbox.

Pre Med Newsletter Icon-1

Partner With Us

Position your AI, computational pathology or diagnostics platform in front of the senior pharma R&D leaders, computational pathologists and digital pathology programme heads shaping the regulatory and operational future of AI-driven diagnostics. Sponsorship options include presentation slots, exhibition space, branded sessions and pre-arranged 1:1 meetings. 

Register Now

Computational pathology and AI in diagnostics, from foundation models to regulatory pathway.
San Diego. 23 – 24 September 2026.


Decision 1

Sentence describing Decision 1

Decision 2

Sentence describing Decision 2